Neuromuscular Disorders
Volume 18, Issue 1 , Pages 45-51 , January 2008

Protein O-mannosyltransferase activities in lymphoblasts from patients with α-dystroglycanopathies

  • Hiroshi Manya

      Affiliations

    • Glycobiology Research Group, Tokyo Metropolitan Institute of Gerontology, Foundation for Research on Aging and Promotion of Human Welfare, Itabashi-ku, Tokyo, Japan
    • The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
    • ,
  • Céline Bouchet

      Affiliations

    • AP-HP, Bichat-Claude Bernard Hospital, Biochimie, INSERM CRB U773, Paris, France
    • The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
    • ,
  • Akiko Yanagisawa

      Affiliations

    • Inserm, U582, Institut de Myologie, Paris, France
    • Université Pierre et Marie Curie-Paris6, UMR S582, IFR14, Paris, France
    • ,
  • Sandrine Vuillaumier-Barrot

      Affiliations

    • AP-HP, Bichat-Claude Bernard Hospital, Biochimie, INSERM CRB U773, Paris, France
    • ,
  • Susana Quijano-Roy

      Affiliations

    • Inserm, U582, Institut de Myologie, Paris, France
    • Université Pierre et Marie Curie-Paris6, UMR S582, IFR14, Paris, France
    • AP-HP, Raymond Poincaré Hospital, Pédiatrie, Garches, France
    • ,
  • Yasushi Suzuki

      Affiliations

    • Department of Applied Chemistry, School of Engineering, Tokai University, Kanagawa, Japan
    • ,
  • Svetlana Maugenre

      Affiliations

    • Inserm, U582, Institut de Myologie, Paris, France
    • Université Pierre et Marie Curie-Paris6, UMR S582, IFR14, Paris, France
    • ,
  • Pascale Richard

      Affiliations

    • Inserm, U582, Institut de Myologie, Paris, France
    • Université Pierre et Marie Curie-Paris6, UMR S582, IFR14, Paris, France
    • AP-HP, Pitié-Salpêtrière Hospital, UF Cardiogénétique et Myogénétique, Paris, France
    • AP-HP, Pitié-Salpêtrière Hospital, Service de Biochimie B, Paris, France
    • ,
  • Toshiyuki Inazu

      Affiliations

    • Department of Applied Chemistry, School of Engineering, Tokai University, Kanagawa, Japan
    • Institute of Glycotechnology, Tokai University, Kanagawa, Japan
    • ,
  • Luciano Merlini

      Affiliations

    • Dipartimento di Medicina Sperimentale e Diagnostica, Sezione di Genetica Medica, Muscle Unit, Università di Ferrara, Italy
    • ,
  • Norma B. Romero

      Affiliations

    • Inserm, U582, Institut de Myologie, Paris, France
    • Université Pierre et Marie Curie-Paris6, UMR S582, IFR14, Paris, France
    • ,
  • France Leturcq

      Affiliations

    • AP-HP, Cochin Hospital, Biochimie et Génétique Moléculaire, 75014 Paris, France
    • ,
  • Isabelle Bezier

      Affiliations

    • Banque de Cellules et d’ADN Genethon, Evry, France
    • ,
  • Haluk Topaloglu

      Affiliations

    • Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey
    • ,
  • Brigitte Estournet

      Affiliations

    • AP-HP, Raymond Poincaré Hospital, Pédiatrie, Garches, France
    • ,
  • Nathalie Seta

      Affiliations

    • AP-HP, Bichat-Claude Bernard Hospital, Biochimie, INSERM CRB U773, Paris, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 40 25 85 43; fax: +331 40 25 88 21.
    • ,
  • Tamao Endo

      Affiliations

    • Glycobiology Research Group, Tokyo Metropolitan Institute of Gerontology, Foundation for Research on Aging and Promotion of Human Welfare, Itabashi-ku, Tokyo, Japan
    • ,
  • Pascale Guicheney

      Affiliations

    • Inserm, U582, Institut de Myologie, Paris, France
    • Université Pierre et Marie Curie-Paris6, UMR S582, IFR14, Paris, France
    • AP-HP, Pitié-Salpêtrière Hospital, Service de Biochimie B, Paris, France

Received 11 May 2007 ,Revised 23 July 2007 ,Accepted 8 August 2007.

References 

  1. Michele DE, Barresi R, Kanagawa M, et al. Post-translational disruption of dystroglycan–ligand interactions in congenital muscular dystrophies. Nature. 2002;418:417–422
  2. Michele DE, Campbell KP. Dystrophin–glycoprotein complex: post-translational processing and dystroglycan and function. J Biol Chem. 2003;278:15457–15460
  3. Muntoni F, Voit T. 133rd ENMC International Workshop on Congenital Muscular Dystrophy (IXth International CMD Workshop) 21–23 January 2005, Naarden, The Netherlands. Neuromuscul Disord. 2005;15:794–801
  4. Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell. 2001;1:717–724
  5. Diesen C, Saarinen A, Pihko H, et al. POMGnT1 mutation and phenotypic spectrum in muscle–eye–brain disease. J Med Genet. 2004;41:e115
  6. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker–Warburg syndrome. Am J Hum Genet. 2002;71:1033–1043
  7. Currier SC, Lee CK, Chang BS, et al. Mutations in POMT1 are found in a minority of patients with Walker–Warburg syndrome. Am J Med Genet A. 2005;133A:53–57
  8. van Reeuwijk J, Brunner HG, van Bokhoven H. Glyc-O-genetics of Walker–Warburg syndrome. Clin Genet. 2005;67:281–289
  9. Kim DS, Hayashi YK, Matsumoto H, et al. POMT1 mutation results in defective glycosylation and loss of laminin-binding activity in alpha-DG. Neurology. 2004;62:1009–1011
  10. van Reeuwijk J, Janssen M, van den Elzen C, et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker Warburg syndrome. J Med Genet. 2005;
  11. Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature. 1998;394:388–392
  12. Longman C, Brockington M, Torelli S, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of α-dystroglycan. Hum Mol Genet. 2003;12:2853–2861
  13. van Reeuwijk J, Grewal PK, Salih MA, et al. Intragenic deletion in the LARGE gene causes Walker–Warburg syndrome. Hum Genet. 2007;121:685–690
  14. Quijano-Roy S, Marti-Carrera I, Makri S, et al. Brain MRI abnormalities in muscular dystrophy due to FKRP mutations. Brain Dev. 2006;28:232–242
  15. Louhichi N, Triki C, Quijano-Roy S, et al. New FKRP mutations causing congenital muscular dystrophy associated with mental retardation and central nervous system abnormalities. Identification of a founder mutation in Tunisian families. Neurogenetics. 2004;5:27–34
  16. Topaloglu H, Brockington M, Yuva Y, et al. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology. 2003;60:988–992
  17. Mercuri E, Topaloglu H, Brockington M, et al. Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch Neurol. 2006;63:251–257
  18. Beltran-Valero de Bernabe D, Voit T, Longman C, et al. Mutations in the FKRP gene can cause muscle–eye–brain disease and Walker–Warburg syndrome. J Med Genet. 2004;41:e61
  19. Biancheri R, Bertini E, Falace A, et al. POMGnT1 mutations in congenital muscular dystrophy: genotype–phenotype correlation and expanded clinical spectrum. Arch Neurol. 2006;63:1491–1495
  20. D’Amico A, Tessa A, Bruno C, et al. Expanding the clinical spectrum of POMT1 phenotype. Neurology. 2006;66:1564–1567discussion 1461
  21. Balci B, Uyanik G, Dincer P, et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker–Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord. 2005;15:271–275
  22. van Reeuwijk J, Maugenre S, van den Elzen C, et al. The expanding phenotype of POMT1 mutations: from Walker–Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation. Hum Mutat. 2006;27:453–459
  23. Yanagisawa A, Bouchet C, Van den Bergh PYK et al. New POMT2 mutations causing congenital muscular dystrophy: identification of a founder mutation. Neurology 2007, in press.
  24. Manya H, Sakai K, Kobayashi K, et al. Loss-of-function of an N-acetylglucosaminyltransferase, POMGnT1, in muscle–eye–brain disease. Biochem Biophys Res Commun. 2003;306:93–97
  25. Vajsar J, Zhang W, Dobyns WB, et al. Carriers and patients with muscle–eye–brain disease can be rapidly diagnosed by enzymatic analysis of fibroblasts and lymphoblasts. Neuromuscul Disord. 2006;16:132–136
  26. Akasaka-Manya K, Manya H, Endo T. Mutations of the POMT1 gene found in patients with Walker–Warburg syndrome lead to a defect of protein O-mannosylation. Biochem Biophys Res Commun. 2004;325:75–79
  27. Manya H, Chiba A, Yoshida A, et al. Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Natl Acad Sci USA. 2004;101:500–505
  28. Taniguchi K, Kobayashi K, Saito K, et al. Worldwide distribution and broader clinical spectrum of muscle–eye–brain disease. Hum Mol Genet. 2003;12:527–534
  29. Zhang W, Vajsar J, Cao P, et al. Enzymatic diagnostic test for muscle–eye–brain type congenital muscular dystrophy using commercially available reagents. Clin Biochem. 2003;36:339–344
  30. Mercuri E, D’Amico A, Tessa A, et al. POMT2 mutation in a patient with ’MEB-like’ phenotype. Neuromuscul Disord. 2006;16:446–448
  31. Xiong H, Kobayashi K, Tachikawa M, et al. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan. Biochem Biophys Res Commun. 2006;350:935–941
  32. Zhang J, Wang Y, Chu Y, et al. Agrin is involved in lymphocytes activation that is mediated by alpha-dystroglycan. FASEB J. 2006;20:50–58

PII: S0960-8966(07)00686-4

doi: 10.1016/j.nmd.2007.08.002

Neuromuscular Disorders
Volume 18, Issue 1 , Pages 45-51 , January 2008

Article Tools

* Image Usage & Resolution